What do I get if I invest? Is it a stock or share?

Hi Robert, When you invest in Eliaz Therapeutics via our Wefunder campaign, you receive a Simple Agreement for Future Equity (SAFE). This isn’t a traditional stock or share immediately, but rather a contractual agreement that converts into equity (ownership in the company) during a future fundraising round, such as our upcoming Series A. The benefit of investing in our SAFE now is that if it converts into equity into the future, this will be at the SAFE's valuation cap rather than the valuati...

I completed the investment form as an email option and was given a strong password to continue but after I completed everything the system said it could not accept my investment from my location. Is this investment opportunity only available in the USA? I am a Canadian resident.

Hi Candace, thank you for your interest in ETI. Certain provinces in Canada can't participate in crowdfunding, at least through WEFunder. There may be alternate ways to do it. What amount were you looking at investing? with gratitude, Isaac

The entity making the investment is a Family Trust. It does not have an EIN. Should I use a social security number

Hi, I think that SS# is fine , but to make sure I am checking with WeFunder and will get back to you ASAP. Thank you for your support and trust in us. all the best, Isaac

I appreciate that you're submitting your Breakthough Designation Application for the FDA that will fast track some of the process, but what's the regulatory path forward and an anticipated timeline for getting this to patients?

Thank you, Jason, for your question. We are currently engaged in non GLP and GLP large animal safety studies, while finalizing the column prototype. The anticipated timeline is to file for XGAL-3 clinical trials approval mid 2025 and start the XGAL-3 therapeutic trials early 2026, possibly late 2025. We are already in discussions with a number of excellent medical centers in the USA and outside the USA that are interested in participating. We are also planning to conduct pre-therapeutic diagn...

how is this different / compared to current available solution like Oxiris , we know is holt the process , it might improve the patient temporarily but wont change the outcome of sepsis ...

XGAL-3 is fundamentally different than Oxiris. OXiris is a blood filtration system used in conjunction with hemodialysis. It is used at a much later stage in the sepsis process, when the patient already has kidney damage/failure that required dialysis in the ICU. It requires high blood flow of 150-200ml/minute. The 90 days outcome of a meta analysis study from 2023 showed that 90-day mortality, ICU and hospital mortality, and length of hospital stay did not improve. XGAL-3 is a highly selecti...

Eliaz Therapeutics Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Awarded FDA Breakthrough Device Designation, validating XGal-3®'s potential to save millions

Addressing critical unmet need: first significant advancement in sepsis treatment in 25 years

Targeting a $62B sepsis treatment market in the USA alone, part of a $1.97T global opportunity

Our technology shuts down the sepsis process within hours in large animal studies

Platform technology with potential applications beyond sepsis, including cancer & fibrotic diseases

Over 60 patents across 34 countries securing our innovative technology

Secured 2 prestigious NIH grants, demonstrating scientific merit and potential for commercialization

Strategic partnership with Terumo BCT for development and commercialization of XGal-3® treatment

Eliaz Therapeutics

Join The Fight Against Sepsis With Our Life-Saving Medical Device: XGal-3®

$3,164,175

Updates

Eliaz Therapeutics

Quick facts

Team profiles

Featured investor profiles

$3,164,175

Updates